Silodosin Recordati Unión Europea - inglés - EMA (European Medicines Agency)

silodosin recordati

recordati ireland ltd - silodosin - prostatic hyperplasia - urologicals, alpha-adrenoreceptor antagonists - treatment of the signs and symptoms of benign prostatic hyperplasia (bph) in adult men.

Sylvant Unión Europea - inglés - EMA (European Medicines Agency)

sylvant

recordati netherlands b.v. - siltuximab - giant lymph node hyperplasia - immunosuppressants - sylvant is indicated for the treatment of adult patients with multicentric castleman’s disease (mcd who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.,

Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) Unión Europea - inglés - EMA (European Medicines Agency)

qarziba (previously dinutuximab beta eusa and dinutuximab beta apeiron)

recordati netherlands b.v. - dinutuximab beta - neuroblastoma - antineoplastic agents - qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.in patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, qarziba should be combined with interleukin 2 (il 2).

Fotivda Unión Europea - inglés - EMA (European Medicines Agency)

fotivda

recordati netherlands b.v. - tivozanib - carcinoma, renal cell - antineoplastic agents - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced rcc. treatment of advanced renal cell carcinoma.,

TRANXENE T-TAB- clorazepate dipotassium tablet Estados Unidos - inglés - NLM (National Library of Medicine)

tranxene t-tab- clorazepate dipotassium tablet

recordati rare diseases, inc. - clorazepate dipotassium (unii: 63fn7g03xy) (clorazepic acid - unii:d51wo0g0l4) - clorazepate dipotassium 7.5 mg - tranxene is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. tranxene tablets are indicated as adjunctive therapy in the management of partial seizures. the effectiveness of tranxene tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. long-term studies in epileptic patients, however, have shown continued therapeutic activity. the physician should reassess periodically the usefulness of the drug for the individual patient. tranxene tablets are indicated for the symptomatic relief of acute alcohol withdrawal. tranxene tablets are contraindicated in patients with a known hypersensitivity to the drug and in those with acute narrow angle glaucoma.

Vitaros 2 mg/g cream Irlanda - inglés - HPRA (Health Products Regulatory Authority)

vitaros 2 mg/g cream

recordati ireland limited - alprostadil - cream - 2 milligram(s)/gram - drugs used in erectile dysfunction; alprostadil - drugs used in erectile dysfunction - treatment of men  18 years of age with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.